EC approves Merck’s bladder cancer combination therapy in adults
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.
Drugs
Health
Pharma
Drugs
Health
Pharma
Merck halts small cell lung cancer immunotherapy drug trial
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
Drugs
Health
Pharma
Daiichi Sankyo to pay Merck $170 million for cancer test drug rights
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
Drugs
Health
Pharma
Roche ends small cell lung cancer trials as results show ‘reduced efficacy’
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.
Drugs
Health
Pharma
FDA rejects Daiichi, Merck, antibody-drug conjugate application
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.
Drugs
Health
Pharma
US regulator clears Merck’s lung therapy after ‘significant’ results
HQ Team March 27, 2024: The US regulator, the Food and Drug Administration, has approved Winrevair therapy of Merck & Co., Inc., to.
Drugs
Health
Pharma
Merck to buy Harpoon for $680 million to step up cancer portfolio
HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.
Drugs
Health
Pharma
Merck & Co meets breast cancer therapy goal in last-stage trials
HQ Team July 29, 2023: Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of.
Drugs
Pharma
Verge Genomics starts human trials with AI drug
Verge Genomics, backed by Eli Lilly and Merck & Co., announced it had dosed a human during clinical trials with a drug discovered.